# DESCRIPTION

## FIELD OF THE INVENTION

- relate to non-human animal model

## BACKGROUND OF THE INVENTION

- introduce diabetic retinopathy
- describe its consequences
- explain role of glial cells
- describe Müller cells' functions
- explain potassium buffering and water drainage
- describe Dp71's role in Kir4.1 and AQP4 expression
- discuss consequences of Dp71 genetic inactivation
- summarize glial cell dysfunction in retinal diseases

## SUMMARY OF THE INVENTION

- introduce non-human animal model for increased retinal vascular permeability

## DETAILED DESCRIPTION OF THE INVENTION

- describe experimental retinal detachment model
- describe results of experimental retinal detachment model

### Non Human Model According to the Invention

- define non human animal model for increased retinal vascular permeability
- describe term "increased retinal vascular permeability"
- define term "Dp71"
- describe Dp71 protein structure
- describe Dp71 transcripts and isoforms
- define term "DAP"
- describe DAPC structure
- describe DAPC components
- describe DAPC function in skeletal muscle
- describe DAPC function in retina
- define "inhibitor of expression"
- describe small organic molecule inhibitors of Dp71 or DAP genes
- describe anti-sense oligonucleotide constructs
- describe siRNA inhibitors of Dp71 or DAP genes
- describe shRNA inhibitors of Dp71 or DAP genes
- describe ribozyme inhibitors of Dp71 or DAP genes
- describe modifications to oligonucleotides for increased stability
- describe vectors for delivering inhibitors of expression
- describe viral vectors
- describe retroviral vectors
- describe adenoviral vectors
- describe adeno-associated viral vectors
- describe plasmid vectors
- describe delivery methods for plasmid vectors
- describe heterologous regulatory regions
- describe specific promoters for Müller glial cells
- describe deficient animals for Dp71 or DAP genes
- describe methods for producing deficient animals
- describe conditional knock-out of targeted genes
- describe example of deficient animal for Dp71
- describe selection of animal models
- describe preferred animal model
- describe use of animal model for screening drugs
- describe use of animal model for studying disease physiopathology
- describe use of animal model for diagnostic or prognostic markers
- describe diseases associated with increased retinal permeability
- describe method for screening drugs
- describe step of providing animal model
- describe step of measuring blood-retinal barrier integrity

### Uses of the Non Human Model According to the Invention

- describe use of animal model for screening drugs
- describe use of animal model for studying disease physiopathology
- describe use of animal model for diagnostic or prognostic markers
- describe method for screening drugs

### Diagnostics Methods According to the Invention

- define subject and biological sample
- describe mutation detection techniques
- describe expression analysis techniques
- detail mRNA/cDNA preparation and hybridization
- describe nucleic acid amplification methods
- describe protein expression analysis techniques
- detail antibody-based detection methods
- describe enzyme immunoassay and radioimmunoassay
- describe Western blot analysis and ELISA
- compare expression levels in biological samples
- define normal expression level

### Therapeutic Methods and Pharmaceutical Compositions According to the Invention

- define treating and treatment
- describe polypeptide production techniques
- describe vector and construct preparation
- describe delivery methods for nucleic acid constructs
- describe in vitro and ex vivo production of polypeptides
- describe activators of expression
- describe therapeutic compositions and formulations
- describe pharmaceutically acceptable excipients and carriers
- describe unit administration forms
- describe oral, sublingual, and subcutaneous administration forms
- describe intramuscular, intravenous, and transdermal administration forms
- describe topical, intraperitoneal, and intranasal administration forms
- describe rectal administration forms
- describe injectable solutions and dispersions
- describe sterile powders for injectable solutions
- describe isotonic agents and antibacterial agents
- describe prolonged absorption agents
- describe sterile injectable solution preparation
- describe dispersion preparation
- describe dosage forms and administration
- describe ophthalmic delivery and formulations

## EXAMPLE

- introduce Dp71-null mice
- describe control mice
- outline animal use guidelines
- introduce antibodies
- describe antibody sources
- outline induction of retinal detachment
- describe anesthesia and pupil dilation
- outline subretinal injection
- exclude animals with complications
- outline immunohistochemistry
- describe fixation and cryoprotection
- outline sectioning and mounting
- describe permeabilization and blocking
- outline primary and secondary antibody incubation
- describe mounting and viewing
- outline Western blot analysis
- describe protein extraction and gel resolution
- outline membrane blocking and antibody incubation
- describe chemiluminescence detection
- outline quantitative RT-PCR analysis
- describe RNA extraction and reverse transcription
- outline PCR amplification and data analysis
- describe glial cell isolation and electrophysiological recordings
- introduce retinal detachment model
- describe immunohistochemistry results
- analyze Western blot and real-time PCR results
- discuss Kir4.1 protein levels
- describe AQP4 distribution and expression
- discuss utrophin localization and expression
- summarize results on Dp71, Kir4.1, and AQP4
- introduce Dp71-null mice model
- describe Kir4.1 and AQP4 in Dp71-null mice
- record membrane currents in Müller cells
- analyze K+ current amplitudes
- discuss current densities
- test for cellular hypertrophy
- analyze membrane capacitance
- discuss K+ current densities
- investigate osmotic Müller cell swelling
- analyze Müller cell somata size
- discuss effects of Ba2+ on Müller cells
- analyze Müller cell swelling in Dp71-null mice
- test for adenosine effects on Müller cells
- analyze effects of phospholipase A2 and cyclooxygenase inhibitors
- discuss BRB permeability in Dp71-null mice
- summarize findings on Dp71 and Müller cells
- discuss role of Dp71 in retinal potassium and water homeostasis
- discuss BRB function and retinal vascular permeability
- discuss osmotic Müller cell swelling and inflammation
- discuss pathomechanisms of edema formation
- discuss role of Müller cells in BRB maintenance
- discuss potential compensatory mechanisms in Dp71-null mice
- conclude on Dp71-null mice as a model for retinal edemas

